Tissue Regenix Group PLC Stock Rating Reaffirmed by Panmure Gordon (TRX)
Tissue Regenix Group PLC (LON:TRX)‘s stock had its “buy” rating reaffirmed by analysts at Panmure Gordon in a research report issued to clients and investors on Tuesday, American Banking News.com reports. They currently have a GBX 18 ($0.29) target price on the stock. Panmure Gordon’s price target would indicate a potential upside of 84.62% from the stock’s previous close.
Shares of Tissue Regenix Group PLC (LON:TRX) opened at 9.75 on Tuesday. Tissue Regenix Group PLC has a 52-week low of GBX 8.50 and a 52-week high of GBX 14.70. The stock’s 50-day moving average is GBX 9.95 and its 200-day moving average is GBX 10.48.
Tissue Regenix Group plc, is a United Kingdom-based holding company. It is a regenerative medical devices company, which uses animal or human tissue to replace damaged or worn out parts of the human body.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.